NCT05501548 - Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

October 14, 2024

Study Completion Date

October 14, 2024

Conditions

Prostate CancerCastration-resistant Prostate Cancer

Interventions

DRUG

Olaparib

Olaparib 300mg by mouth twice daily

DIETARY_SUPPLEMENT

Vitamin C

Ascorbic acid 1g/kg administered intravenously twice weekly

Trial Locations (2)

Sibley Memorial Hospital, Washington D.C.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore